HEADER TRANSFERASE 21-MAY-20 6X3O TITLE CO-STRUCTURE OF BTK KINASE DOMAIN WITH L-005191930 INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: TYROSINE-PROTEIN KINASE BTK; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: AGAMMAGLOBULINEMIA TYROSINE KINASE, ATK, B-CELL PROGENITOR COMPND 5 KINASE, BPK, BRUTON TYROSINE KINASE; COMPND 6 EC: 2.7.10.2; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BTK, AGMX1, ATK, BPK; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 9 EXPRESSION_SYSTEM_CELL_LINE: SF21 KEYWDS BRUTON TYROSINE KINASE INHIBITOR, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR T.O.FISCHMANN REVDAT 3 06-MAR-24 6X3O 1 REMARK REVDAT 2 12-AUG-20 6X3O 1 JRNL REVDAT 1 22-JUL-20 6X3O 0 JRNL AUTH J.LIU,D.GUIADEEN,A.KRIKORIAN,X.GAO,J.WANG,S.BABU BOGA, JRNL AUTH 2 A.B.ALHASSAN,W.YU,O.SELYUTIN,Y.YU,R.ANAND,J.XU,J.KELLY, JRNL AUTH 3 J.L.DUFFY,S.LIU,C.YANG,H.WU,J.CAI,C.BENNETT,K.M.MALONEY, JRNL AUTH 4 S.TYAGARAJAN,Y.D.GAO,T.O.FISCHMANN,J.PRESLAND,M.MANSUETO, JRNL AUTH 5 Z.XU,E.LECCESE,J.ZHANG-HOOVER,I.KNEMEYER,C.G.GARLISI, JRNL AUTH 6 P.STIVERS,P.E.BRANDISH,A.HICKS,R.KIM,J.A.KOZLOWSKI JRNL TITL POTENT, NON-COVALENT REVERSIBLE BTK INHIBITORS WITH JRNL TITL 2 8-AMINO-IMIDAZO[1,5-A]PYRAZINE CORE FEATURING 3-POSITION JRNL TITL 3 BICYCLIC RING SUBSTITUTES. JRNL REF BIOORG.MED.CHEM.LETT. V. 30 27390 2020 JRNL REFN ESSN 1464-3405 JRNL PMID 32738973 JRNL DOI 10.1016/J.BMCL.2020.127390 REMARK 2 REMARK 2 RESOLUTION. 1.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 34.79 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 3 NUMBER OF REFLECTIONS : 44309 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.181 REMARK 3 R VALUE (WORKING SET) : 0.179 REMARK 3 FREE R VALUE : 0.213 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 2215 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.95 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 98.95 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 3189 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2082 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 3033 REMARK 3 BIN R VALUE (WORKING SET) : 0.2064 REMARK 3 BIN FREE R VALUE : 0.2445 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.89 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 156 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.000 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4353 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 156 REMARK 3 SOLVENT ATOMS : 344 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 27.01 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 33.50 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 2.08950 REMARK 3 B22 (A**2) : 0.15460 REMARK 3 B33 (A**2) : -2.24410 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 1.28120 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.199 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.149 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.132 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.279 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.134 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.948 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.932 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 9042 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 16266 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 2027 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 112 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 1284 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 9042 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 558 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 9805 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 0.99 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.43 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 15.11 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6X3O COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 22-MAY-20. REMARK 100 THE DEPOSITION ID IS D_1000249343. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-JUN-14 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1. REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS 0.1.27 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 44327 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.900 REMARK 200 RESOLUTION RANGE LOW (A) : 34.790 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 200 DATA REDUNDANCY : 2.900 REMARK 200 R MERGE (I) : 0.06900 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 10.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.12 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.3 REMARK 200 DATA REDUNDANCY IN SHELL : 2.90 REMARK 200 R MERGE FOR SHELL (I) : 0.32000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: BUSTER-TNT REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 45.99 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.28 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1M BIS-TRIS CL PH 7.5, 18%W/VPEG REMARK 280 20,000, 5MM 4-(8-AMINO-3-((6R,8AS)-3-OXOOCTAHYDROINDOLIZIN-6-YL) REMARK 280 IMIDAZO[1,5-A]PYRAZIN-1-YL)-3-METHOXY-N-(4-(TRIFLUOROMETHYL) REMARK 280 PYRIDIN-2-YL)BENZAMIDE, 5MM (S)-4-(8-AMINO-3-(1-(4- REMARK 280 (DIMETHYLAMINO)BUTANOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1- REMARK 280 YL)-N-(THIAZOL-2-YL)BENZAMIDE, 10% V/V DEUTERATED-DMSO, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 36.00500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 389 REMARK 465 LEU A 390 REMARK 465 GLY A 391 REMARK 465 TYR A 392 REMARK 465 GLY A 393 REMARK 465 SER A 394 REMARK 465 GLY B 389 REMARK 465 LEU B 390 REMARK 465 GLY B 391 REMARK 465 TYR B 392 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 SER A 659 C O CB OG REMARK 470 GLY B 393 N REMARK 470 SER B 659 C O CB OG REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE A 413 42.18 72.95 REMARK 500 LYS A 466 50.98 -90.12 REMARK 500 GLN A 467 159.19 169.08 REMARK 500 ARG A 520 -14.06 81.79 REMARK 500 ASP A 521 44.46 -148.82 REMARK 500 GLN B 424 -41.90 -147.02 REMARK 500 LYS B 466 50.95 -90.32 REMARK 500 GLN B 467 159.85 169.42 REMARK 500 ARG B 520 -11.96 80.45 REMARK 500 ASP B 521 42.95 -149.82 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: PLANAR GROUPS REMARK 500 REMARK 500 PLANAR GROUPS IN THE FOLLOWING RESIDUES HAVE A TOTAL REMARK 500 RMS DISTANCE OF ALL ATOMS FROM THE BEST-FIT PLANE REMARK 500 BY MORE THAN AN EXPECTED VALUE OF 6*RMSD, WITH AN REMARK 500 RMSD 0.02 ANGSTROMS, OR AT LEAST ONE ATOM HAS REMARK 500 AN RMSD GREATER THAN THIS VALUE REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI RMS TYPE REMARK 500 TYR A 545 0.06 SIDE CHAIN REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ULY A 701 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 5WE A 702 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ULY B 701 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 5WE B 702 DBREF 6X3O A 389 659 UNP Q06187 BTK_HUMAN 389 659 DBREF 6X3O B 389 659 UNP Q06187 BTK_HUMAN 389 659 SEQRES 1 A 271 GLY LEU GLY TYR GLY SER TRP GLU ILE ASP PRO LYS ASP SEQRES 2 A 271 LEU THR PHE LEU LYS GLU LEU GLY THR GLY GLN PHE GLY SEQRES 3 A 271 VAL VAL LYS TYR GLY LYS TRP ARG GLY GLN TYR ASP VAL SEQRES 4 A 271 ALA ILE LYS MET ILE LYS GLU GLY SER MET SER GLU ASP SEQRES 5 A 271 GLU PHE ILE GLU GLU ALA LYS VAL MET MET ASN LEU SER SEQRES 6 A 271 HIS GLU LYS LEU VAL GLN LEU TYR GLY VAL CYS THR LYS SEQRES 7 A 271 GLN ARG PRO ILE PHE ILE ILE THR GLU TYR MET ALA ASN SEQRES 8 A 271 GLY CYS LEU LEU ASN TYR LEU ARG GLU MET ARG HIS ARG SEQRES 9 A 271 PHE GLN THR GLN GLN LEU LEU GLU MET CYS LYS ASP VAL SEQRES 10 A 271 CYS GLU ALA MET GLU TYR LEU GLU SER LYS GLN PHE LEU SEQRES 11 A 271 HIS ARG ASP LEU ALA ALA ARG ASN CYS LEU VAL ASN ASP SEQRES 12 A 271 GLN GLY VAL VAL LYS VAL SER ASP PHE GLY LEU SER ARG SEQRES 13 A 271 TYR VAL LEU ASP ASP GLU TYR THR SER SER VAL GLY SER SEQRES 14 A 271 LYS PHE PRO VAL ARG TRP SER PRO PRO GLU VAL LEU MET SEQRES 15 A 271 TYR SER LYS PHE SER SER LYS SER ASP ILE TRP ALA PHE SEQRES 16 A 271 GLY VAL LEU MET TRP GLU ILE TYR SER LEU GLY LYS MET SEQRES 17 A 271 PRO TYR GLU ARG PHE THR ASN SER GLU THR ALA GLU HIS SEQRES 18 A 271 ILE ALA GLN GLY LEU ARG LEU TYR ARG PRO HIS LEU ALA SEQRES 19 A 271 SER GLU LYS VAL TYR THR ILE MET TYR SER CYS TRP HIS SEQRES 20 A 271 GLU LYS ALA ASP GLU ARG PRO THR PHE LYS ILE LEU LEU SEQRES 21 A 271 SER ASN ILE LEU ASP VAL MET ASP GLU GLU SER SEQRES 1 B 271 GLY LEU GLY TYR GLY SER TRP GLU ILE ASP PRO LYS ASP SEQRES 2 B 271 LEU THR PHE LEU LYS GLU LEU GLY THR GLY GLN PHE GLY SEQRES 3 B 271 VAL VAL LYS TYR GLY LYS TRP ARG GLY GLN TYR ASP VAL SEQRES 4 B 271 ALA ILE LYS MET ILE LYS GLU GLY SER MET SER GLU ASP SEQRES 5 B 271 GLU PHE ILE GLU GLU ALA LYS VAL MET MET ASN LEU SER SEQRES 6 B 271 HIS GLU LYS LEU VAL GLN LEU TYR GLY VAL CYS THR LYS SEQRES 7 B 271 GLN ARG PRO ILE PHE ILE ILE THR GLU TYR MET ALA ASN SEQRES 8 B 271 GLY CYS LEU LEU ASN TYR LEU ARG GLU MET ARG HIS ARG SEQRES 9 B 271 PHE GLN THR GLN GLN LEU LEU GLU MET CYS LYS ASP VAL SEQRES 10 B 271 CYS GLU ALA MET GLU TYR LEU GLU SER LYS GLN PHE LEU SEQRES 11 B 271 HIS ARG ASP LEU ALA ALA ARG ASN CYS LEU VAL ASN ASP SEQRES 12 B 271 GLN GLY VAL VAL LYS VAL SER ASP PHE GLY LEU SER ARG SEQRES 13 B 271 TYR VAL LEU ASP ASP GLU TYR THR SER SER VAL GLY SER SEQRES 14 B 271 LYS PHE PRO VAL ARG TRP SER PRO PRO GLU VAL LEU MET SEQRES 15 B 271 TYR SER LYS PHE SER SER LYS SER ASP ILE TRP ALA PHE SEQRES 16 B 271 GLY VAL LEU MET TRP GLU ILE TYR SER LEU GLY LYS MET SEQRES 17 B 271 PRO TYR GLU ARG PHE THR ASN SER GLU THR ALA GLU HIS SEQRES 18 B 271 ILE ALA GLN GLY LEU ARG LEU TYR ARG PRO HIS LEU ALA SEQRES 19 B 271 SER GLU LYS VAL TYR THR ILE MET TYR SER CYS TRP HIS SEQRES 20 B 271 GLU LYS ALA ASP GLU ARG PRO THR PHE LYS ILE LEU LEU SEQRES 21 B 271 SER ASN ILE LEU ASP VAL MET ASP GLU GLU SER HET ULY A 701 41 HET 5WE A 702 37 HET ULY B 701 41 HET 5WE B 702 37 HETNAM ULY 4-{8-AMINO-3-[(6R,8AS)-3-OXO-3,5,6,7,8,8A- HETNAM 2 ULY HEXAHYDROINDOLIZIN-6-YL]IMIDAZO[1,5-A]PYRAZIN-1-YL}-3- HETNAM 3 ULY METHOXY-N-[4-(TRIFLUOROMETHYL)PYRIDIN-2-YL]BENZAMIDE HETNAM 5WE 4-[8-AZANYL-3-[(2~{S})-1-[4-(DIMETHYLAMINO) HETNAM 2 5WE BUTANOYL]PYRROLIDIN-2-YL]IMIDAZO[1,5-A]PYRAZIN-1-YL]- HETNAM 3 5WE ~{N}-(1,3-THIAZOL-2-YL)BENZAMIDE FORMUL 3 ULY 2(C28 H26 F3 N7 O3) FORMUL 4 5WE 2(C26 H30 N8 O2 S) FORMUL 7 HOH *344(H2 O) HELIX 1 AA1 ASP A 398 LYS A 400 5 3 HELIX 2 AA2 SER A 438 MET A 450 1 13 HELIX 3 AA3 CYS A 481 GLU A 488 1 8 HELIX 4 AA4 MET A 489 ARG A 492 5 4 HELIX 5 AA5 GLN A 494 LYS A 515 1 22 HELIX 6 AA6 ALA A 523 ARG A 525 5 3 HELIX 7 AA7 GLY A 541 VAL A 546 5 6 HELIX 8 AA8 ASP A 548 SER A 553 1 6 HELIX 9 AA9 PRO A 560 SER A 564 5 5 HELIX 10 AB1 PRO A 565 SER A 572 1 8 HELIX 11 AB2 SER A 575 SER A 592 1 18 HELIX 12 AB3 THR A 602 GLN A 612 1 11 HELIX 13 AB4 SER A 623 CYS A 633 1 11 HELIX 14 AB5 LYS A 637 ARG A 641 5 5 HELIX 15 AB6 THR A 643 SER A 659 1 17 HELIX 16 AB7 ASP B 398 LYS B 400 5 3 HELIX 17 AB8 SER B 438 MET B 450 1 13 HELIX 18 AB9 CYS B 481 GLU B 488 1 8 HELIX 19 AC1 MET B 489 ARG B 492 5 4 HELIX 20 AC2 GLN B 494 LYS B 515 1 22 HELIX 21 AC3 ALA B 523 ARG B 525 5 3 HELIX 22 AC4 GLY B 541 VAL B 546 5 6 HELIX 23 AC5 ASP B 548 SER B 553 1 6 HELIX 24 AC6 PRO B 560 SER B 564 5 5 HELIX 25 AC7 PRO B 565 SER B 572 1 8 HELIX 26 AC8 SER B 575 SER B 592 1 18 HELIX 27 AC9 THR B 602 GLN B 612 1 11 HELIX 28 AD1 SER B 623 CYS B 633 1 11 HELIX 29 AD2 LYS B 637 ARG B 641 5 5 HELIX 30 AD3 THR B 643 SER B 659 1 17 SHEET 1 AA1 5 LEU A 402 GLY A 411 0 SHEET 2 AA1 5 GLY A 414 TRP A 421 -1 O TYR A 418 N LYS A 406 SHEET 3 AA1 5 TYR A 425 ILE A 432 -1 O ILE A 429 N LYS A 417 SHEET 4 AA1 5 PHE A 471 THR A 474 -1 O THR A 474 N ALA A 428 SHEET 5 AA1 5 LEU A 460 CYS A 464 -1 N TYR A 461 O ILE A 473 SHEET 1 AA2 2 CYS A 527 VAL A 529 0 SHEET 2 AA2 2 VAL A 535 VAL A 537 -1 O LYS A 536 N LEU A 528 SHEET 1 AA3 5 LEU B 402 GLY B 411 0 SHEET 2 AA3 5 GLY B 414 TRP B 421 -1 O TYR B 418 N LYS B 406 SHEET 3 AA3 5 TYR B 425 ILE B 432 -1 O MET B 431 N VAL B 415 SHEET 4 AA3 5 PHE B 471 THR B 474 -1 O THR B 474 N ALA B 428 SHEET 5 AA3 5 LEU B 460 CYS B 464 -1 N TYR B 461 O ILE B 473 SHEET 1 AA4 2 CYS B 527 VAL B 529 0 SHEET 2 AA4 2 VAL B 535 VAL B 537 -1 O LYS B 536 N LEU B 528 CISPEP 1 ARG A 468 PRO A 469 0 3.12 CISPEP 2 ARG B 468 PRO B 469 0 3.10 SITE 1 AC1 21 LEU A 408 GLY A 411 VAL A 416 ALA A 428 SITE 2 AC1 21 LYS A 430 PHE A 442 MET A 449 LEU A 460 SITE 3 AC1 21 ILE A 472 THR A 474 GLU A 475 MET A 477 SITE 4 AC1 21 GLY A 480 CYS A 481 ASN A 484 LEU A 528 SITE 5 AC1 21 SER A 538 ASP A 539 LEU A 542 HOH A 863 SITE 6 AC1 21 HOH A 865 SITE 1 AC2 7 TRP A 395 ILE A 397 TRP A 421 TYR A 425 SITE 2 AC2 7 VAL A 427 SER A 453 TYR A 461 SITE 1 AC3 19 LEU B 408 VAL B 416 ALA B 428 ILE B 429 SITE 2 AC3 19 LYS B 430 PHE B 442 MET B 449 LEU B 460 SITE 3 AC3 19 ILE B 472 THR B 474 GLU B 475 MET B 477 SITE 4 AC3 19 GLY B 480 CYS B 481 LEU B 528 SER B 538 SITE 5 AC3 19 ASP B 539 HOH B 814 HOH B 854 SITE 1 AC4 8 SER B 394 TRP B 421 TYR B 425 VAL B 427 SITE 2 AC4 8 SER B 453 TYR B 461 HOH B 885 HOH B 936 CRYST1 38.300 72.010 104.390 90.00 91.40 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.026110 0.000000 0.000638 0.00000 SCALE2 0.000000 0.013887 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009582 0.00000